Risk of Alzheimer's disease is associated with a very low-density lipoprotein receptor genotype in Northern Ireland

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 88, Issue 2, 1999, Pages 140-144

  McIlroy, Stephen P ^a   Vahidassr, M Djamil ^a   Savage, David A ^a   Patterson, Christopher C ^a   Lawson, John T ^b   Passmore, A Peter ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; APOE; VLDL R

Indexed keywords

APOLIPOPROTEIN E; LIPOPROTEIN RECEPTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; PRIORITY JOURNAL; RECEPTOR GENE; RISK FACTOR; TRINUCLEOTIDE REPEAT;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HUMANS; MALE; NORTHERN IRELAND; RECEPTORS, LDL; RISK; TRINUCLEOTIDE REPEATS;

EID: 0033574382     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(19990416)88:2<140::AID-AJMG9>3.0.CO;2-D     Document Type: Article

References (22)

1. American Psychiatric Association. 1994. Diagnostic and statistic manual of mental disorders. 4th edn. Washington, DC: American Psychiatric Association.
2. Brookes AJ, Howell WM, Woodburn K, Johnstone EC, Carothers A. 1997. Presenilin-1, presenilin-2, and VLDL-R associations in early onset Alzheimer's Disease. Lancet 350:336-337.
3. Chung H, Roberts CT, Greenberg S, Rebeck GW, Christie R, Wallace R, Jacob HJ, Hyman BT. 1996. Lack of association of trinucleotide repeat polymorphisms in the very-low-density lipoprotein receptor gene with Alzheimer's disease. Ann Neurol 39:800-803.
4. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
5. Crook R, Hardy J, Duff K. 1994. Single-day apolipoprotein E genotyping. J Neurosci Methods 53:125-127.
6. Edwards JH. 1974. HL-A and disease, the detection of associations. J Immunogenet 1:249-257.
7. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM, for the APOE and Alzheimer Disease Meta Analysis Consortium. 1997. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA 278:1349-1356.
8. Folstein MF, Folstein SE, McHugh PR. 1975. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
9. Goate A, Chartier-Harlin M, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance MA, Roses AD, Williamson R, Rossor M, Owen M, Hardy J. 1991. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-706.
10. Ignatius MJ, Gebicke-Harter PJ, Skene JHP, Schilling JW, Weisgraber KH, Mahley RW, Shooter EM. 1986. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci USA 83:1125-1129.
11. Jokinen E, Sakai J, Yamamoto T, Hobbs HH. 1994. CGG triple repeat polymorphism in the VLDL receptor (VLDL-R) gene. Hum Mol Genet 3:521.
12. Kamboh MI. 1995. Apolipoprotein E polymorphism and susceptibility to Alzheimer's disease. Hum Biol 67:195-215.
13. Lendon CL, Talbot CJ, Craddock NJ, Han SW, Wragg M, Morris JC, Goate AJ. 1997. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Neurosci Lett 222:187-190.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer Disease. Neurology 24: 939-944.
15. Miller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 13: 1215.
16. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. 1994. Differential effects of apolipoproteins E3 andE4 on neuronal growth in vitro. Science 264:850-852.
17. Okuizumi K, Onodera O, Namba Y, Ikeda K, Yamamoto T, Seki K, Ueki A, Nanko S, Tanaka H, Takahashi H, Oyanagi K, Mizusawa H, Kanazawa I, Tsuji S. 1995. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat Genet 11:207-209.
18. Okuizumi O, Onodera O, Seki K, Tanaka H, Namba Y, Ikeda K, Saunders AM, Pericak-Vance MA, Roses AD, Tsuji S. 1996. Lack of association of very low density lipoprotein receptor gene polymorphism with Caucasian Alzheimer's disease. Ann Neurol 40:251-254.
19. Pato CN, Azevedo MH, Pato MT, Kennedy JL, Coelho I, Dourado A, Macedo A, Valente J, Paz Ferreira C, Madeira J, Gago da Camara J, Moniz M, Correia C. 1997. Selection of homogeneous populations for genetic study: The Portugal Genetics of Psychosis Project. Am J Med Genet 74:286-288.
20. Pericak-Vance MA, Haines JL. 1995. Genetic susceptibility to Alzheimer disease. TIGS 11:504-508.
21. Pitas RE, Boyles JK, Lee SH, Hui DY, Weisgraber KH. 1987. Lipoproteins and their receptors in the central nervous system: Characterisation of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain. J Biol Chem 262:14352-14360.
22. Prichard ML, Saunders AM, Gaskell PC, Small GW, Conneally PM, Rosi B, Yamaoka LH, Roses AD, Haines JL, Pericak-Vance MA. 1996. No association between very low density lipoprotein receptor (VLDL-R) and Alzheimer disease in American Caucasians. Neurosci Lett 209:105108.